The vitamin K shot given to newborns is safe. It has been standard practice for over 50 years, recommended by the American Academy of Pediatrics and pediatric organizations worldwide. The injection contains a tiny dose of vitamin K1, a natural nutrient, and serious adverse reactions are extraordinarily rare. Meanwhile, skipping the shot leaves a baby vulnerable to dangerous bleeding that can cause brain damage or death.
Why Newborns Need Vitamin K
Vitamin K is essential for blood clotting. Adults get it from food and from bacteria in their gut, but newborns start life with very little. The placenta transfers only small amounts during pregnancy, and a baby’s intestines haven’t yet built up the bacteria that produce it. Breast milk also contains relatively low levels of vitamin K.
This shortage means newborns can’t produce enough clotting factors to stop bleeding on their own. Without supplementation, roughly 1 in 60 babies will develop some form of vitamin K deficiency bleeding (VKDB). The condition comes in three forms: early (within the first 24 hours), classic (during the first week), and late (between 2 weeks and 6 months of age). Late VKDB is rarer, occurring in about 1 in 14,000 to 1 in 25,000 infants, but it often involves bleeding inside the brain. Infants who don’t receive the shot are 81 times more likely to develop late VKDB than those who do.
What’s in the Shot
The active ingredient is phytonadione, which is simply the pharmaceutical name for vitamin K1, the same form found in leafy green vegetables. A newborn receives 1 mg in a 0.5 mL injection, given in the thigh muscle within the first six hours of life. Premature babies weighing under about 3.3 pounds receive a smaller dose adjusted to their weight.
The inactive ingredients are straightforward: polysorbate 80 (an emulsifier used widely in foods and medications), propylene glycol (a stabilizer also found in many food products), sodium acetate, acetic acid, and water. There are no live ingredients, no antibiotics, and no mercury-containing preservatives. Some parents specifically ask about preservative-free options. At least one U.S. manufacturer, International Medication Systems, produces a formulation marketed as preservative-free vitamin K.
Known Side Effects
The most common reaction is minor soreness, redness, or swelling at the injection site, which resolves on its own. Some babies cry briefly during the shot, as with any injection.
Serious reactions are vanishingly rare. Allergic reactions (anaphylaxis) have been reported, but almost exclusively after intravenous administration in adults, not intramuscular injection in infants. A skin reaction resembling a small hardened patch at the injection site has been documented in seven infants across the medical literature, typically after repeated injections rather than the single newborn dose. Given that millions of doses are administered every year, the risk profile is extremely favorable.
The Leukemia Concern Has Been Thoroughly Studied
In the early 1990s, a single study suggested a possible link between the vitamin K shot and childhood leukemia. This finding prompted extensive investigation across multiple countries. The largest and most comprehensive study, conducted in the United Kingdom, compared over 2,500 children with cancer (including more than 1,000 with leukemia) to nearly 4,500 healthy controls. It found no association between the intramuscular vitamin K shot and leukemia or any other childhood cancer.
That conclusion has been confirmed repeatedly. At least nine major studies and a pooled analysis of six large case-control studies all reached the same result. The original concern has been firmly put to rest by the scientific evidence.
Oral Vitamin K Is Less Reliable
Some parents ask about oral vitamin K drops as an alternative to the injection. While oral regimens exist and are used in some European countries, they are less effective. A German study found that the rate of late VKDB after a single oral dose was 1.4 per 100,000 infants, compared to 0.25 per 100,000 after the intramuscular injection. That makes the oral route roughly 5 to 28 times less protective, depending on the study.
The reasons are biological. By four to six weeks of age, up to 19% of babies who received an oral dose at birth showed biochemical signs of vitamin K deficiency, compared to only 5.5% of those who received the injection. The shot creates a muscle depot that releases vitamin K slowly over weeks, while oral doses are absorbed less consistently and clear the body faster. Oral regimens also require multiple doses over weeks, and missed doses increase the risk of failure. The AAP recommends the intramuscular injection exclusively for these reasons.
What Happens Without the Shot
VKDB can range from mild bruising and bleeding from the umbilical cord to life-threatening internal hemorrhage. Late-onset VKDB is particularly dangerous because it often presents suddenly, with bleeding inside the skull. In 2013, the CDC reported a cluster of late VKDB cases in Tennessee among infants whose parents had declined the shot. These cases are preventable.
Exclusively breastfed babies face higher risk because breast milk contains less vitamin K than formula (which is fortified). This doesn’t mean breastfeeding is a problem. It means the shot is especially important for breastfed infants, filling the gap until the baby starts eating solid foods and developing gut bacteria that produce vitamin K naturally.